Latest News

2021

12 April, 2021 Press Releases Press Releases 2021
Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting

2020

16 December, 2020 Press Releases Press Releases 2020
Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564
06 December, 2020 Press Releases Press Releases 2020
Novel AML patient selection assay for AMV564, Amphivena’s lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting
09 November, 2020 Press Releases Press Releases 2020
Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
23 June, 2020 Press Releases Press Releases 2020
Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564 at the AACR 2020 Virtual Annual Meeting II
17 June, 2020 Press Releases Press Releases 2020
Amphivena Announces Upcoming Oral Presentation at AACR Virtual Annual Meeting II
29 May, 2020 Press Releases Press Releases 2020
Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020
28 May, 2020 Press Releases Press Releases 2020
Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference
14 May, 2020 Press Releases Press Releases 2020
Clinical Data for Amphivena Therapeutics’ Lead Program to be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

2019

2018

03 December, 2018 Press Releases Press Releases 2018
Amphivena Presents at ASH First-in -Human Phase 1 Clinical Data on AMV564

2017

2016

10 August, 2016 Press Releases Press Releases 2016
Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation

2015